T2 Biosystems (TTOO) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results
November 4, 2014 4:00 PM ESTLEXINGTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq: TTOO) today reported operating highlights and financial results for the third quarter ended September 30, 2014. Highlights of the quarter included:
In September, the Company received authorization from the U.S. Food and Drug Administration (FDA) to market its first two products, the T2Candida® Panel and the T2Dx® Instrument for the detection of Candida species in whole blood specimens from patients with symptoms of, or... More


